Welcome to the Newsroom
04 August 2015
Prima BioMed terminates Investment Facility with Bergen Global Opportunity Fund, LP
SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima” or the “Company”), a leading immuno-oncology company, advised that its investment facility with Bergen Global Opportunity Fund, a New York institutional investor managed by Bergen Asset Management, has been terminated by mutual consent.
Article as pdf